Antitumor activity of sorafenib on colorectal cancer
Received Date : 20 Mar 2016
Accepted Date : 28 Jul 2016
Doi: - Article's Language: EN
Journal of Oncological Science 2 (2016) 53-57
This is an open access article under the CC BY-NC-ND license
In spite of progress in treatment on colorectal cancer, it is not still convincing. Because of that, there is a pursuit to find a better treatment option. Our goal of this study is to research antiproliferative effect and mechanism of action of sorafenib on colorectal cancer cell line. Antiproliferative effects of sorafenib have been evaluated by using colorectal DLD-1 cell line. Materials and Methods: For determining the effects of sorafenib on colorectal cell, Real time analysis was performed. Chorioallantoic membrane model (CAM) was used for assessing angiogenesis. Different concentrations of sorafenib (500, 250, 125, 62.5, 31.25, 15.62, 7.81, 3.9, 1.95, 0.97 and 0.48 nM/well) applied on DLD-1 colorectal cancer cells, caused strong antiproliferative effect in a concentration manner. IC50 value of sorafenib was 1.26 × 10-9 M. Sorafenib (100, 10 and 1 nM) also showed strong angiogenic effect in CAM model with scores 1.05, 0.75 and 0.55. The present study indicates that sorafenib has strong antitumor and antiangiogenic affect. These important features make it valuable treatment agent for colorectal cancer which is strongly connected to angiogenic factors. In order to verify and enlighten antitumor mechanism of sorafenib, there is still need for further investigations.